BCRX earnings call for the period ending March 31, 2020.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. “This is a transformational year for BioCryst as we prepare to launch berotralstat in multiple territories to bring our oral, once-daily prophylactic medicine to HAE patients, and begin generating significant revenue,” said Jon Stonehouse, president and chief executive officer of BioCryst. “We are excited to see the clinical response in treatment-naïve PNH patents at the 50 mg and 100 mg twice-daily dose levels, and more than 98 percent suppression of complement in both alternative pathway assays at the 200 mg and 400 mg twice-daily levels in healthy volunteers,” said Dr. William Sheridan, chief medical officer of BioCryst.
Q1 2020 BioCryst Pharmaceuticals Inc Earnings Call
BioCryst (BCRX) delivered earnings and revenue surprises of 7.69% and 78.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
Celebrations may be in order for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shareholders, with the analysts...
This article sets forth various theoretical options strategies for BCRX and analyses which is the best among them.BioCryst stock has shown strong movement in the last month.Preclinical data, as we discussed in our last article, supports a prediction for posit…
BioCryst Pharmaceuticals, Inc. (BCRX) announced today that it is offering to sell $100 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount equal to up to 15% of the securities offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced companywide activities in support of hae day :-) 2020, a global awareness day for hereditary angioedema (HAE). Since actual community walks cannot currently be organized, BioCryst employees around the world are joining virtually with others supporting hae day :-) by logging their steps and photographing their activities to raise awareness of HAE. “HAE is a rare genetic disorder that causes swelling to various parts of the body, and can be fatal when the swelling affects the throat due to the risk of suffocation,” said Henrik Balle Boysen, executive vice president and chief operating officer of HAE International, the international patient organization leading hae day :-).
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 16/671,649. The resulting U.S. patent, once issued, will extend the patent protection for berotralstat (BCX7353) in the United States by four years through October 2039. The U.S. Food and Drug Administration is reviewing a new drug application (NDA) for approval of oral, once-daily berotralstat for the prevention of hereditary angioedema attacks.
Is (BCRX) Outperforming Other Medical Stocks This Year?
BioCryst Pharmaceuticals, Inc. (BCRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Q1 2020 BioCryst Pharmaceuticals Inc Earnings Call
In addition, and in lieu of common stock, BioCryst is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock at a purchase price of $4.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering to BioCryst are expected to be $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst. BioCryst has granted the underwriters a 30-day option to purchase up to an additional 3,333,334 shares of its common stock.
NEW YORK, May 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, BCRX, AAL, RVLV, and MSFT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sele…
Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.
On the cusp of launching berotralstat as a treatment for hereditary angioedema in the U.S. and EU, BioCryst Pharmaceuticals (NASDAQ: BCRX) is planning to sell $100 million of stock in a secondary offering. Of course, with shares up 142% since BioCryst announced last month that it was testing its antiviral medication galidesivir in patients with COVID-19, now seems like as good a time as any to grab some additional cash. BioCryst was trading down 4% in after hours trading on the news of the secondary offering that will dilute shareholders by about 13%.
NEW YORK, May 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, BCRX, AAL, RVLV, and MSFT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sele…
Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Medical Officer, Dr. Bill Sheridan; Chief Business Officer, Megan Sniecinski; and Chief Commercial Officer, Charlie Gayer. Following our remarks, we will answer your questions.
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are up 13% at 2:09 p.m., continuing a two-day run that's seen its shares increase 36% since the close on Thursday. It appears investors are excited about the prospects for its antiviral galidesivir as a treatment for COVID-19, the disease caused by the novel coronavirus. The drug is under review by the Food and Drug Administration, the Pharmaceuticals and Medical Devices Agency in Japan, and the European Medicines Agency.
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Archer Daniels Midland Co (NYSE: ADM) is a chronic underperformer. Those who like it for yield, should buy Verizon Communications Inc. (NYSE: VZ) instead, thinks Cramer.Cramer said Scorpio Tankers In…
RESEARCH TRIANGLE PARK, N.C., May 07, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2020 Healthcare.
BioCryst is up hugely on expectation of positive results for galidesivir in SARS-CoV-2.We discuss available past data of the adenosine analog galidesivir in the coronavirus family.While the results are inconclusive, as expected - (or why would we need a trial…
This article sets forth various theoretical options strategies for BCRX and analyses which is the best among them.BioCryst stock has shown strong movement in the last month.Preclinical data, as we discussed in our last article, supports a prediction for posit…
RESEARCH TRIANGLE PARK, N.C., May 26, 2020 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present new data on berotralstat (BCX7353), an.
Tuesday's top analyst upgrades and downgrades included AppFolio, BioCryst Pharmaceuticals, Booking, DraftKings, Intuit, L Brands, Peloton Interactive, Salesforce.com and Wells Fargo.
As of late, it has definitely been a great time to be an investor in BioCryst Pharmaceuticals.
Q1 2020 BioCryst Pharmaceuticals Inc Earnings Call
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) fell 2% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 14.29% over the past year to ($0.24), which beat the estimate of ($0.25).Revenue of $4,823,000 lower by 18.07% year over year, which beat the estimate of $4,290,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 06, 2020View more earnings on BCRXWebcast URL: https://edge.media-server.com/mmc/p/6c8z23o6Recent Stock Performance Company's 52-week high was at $8.1552-week low: $1.38Price action over last quarter: down 2.68%Company Description BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.See more from Benzinga * Morning Market Stats in 5 Minutes * 20 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease